Advertisement
Response from Dr. Henry

Gynecomastia is a frustrating problem for patients as you well describe. The exact cause is often hard to pin down and treatment is often suboptimal. I have seen no data on the safety /efficacy of Letrozole for HIV-associated gynecomastia. The rate of Sustiva related gynecomastia is low overall so published meaningful data is sparse (one paper reported 5 cases from one large cohort). If no other cause for gynecomastia is found then a switch off Sustiva to an alternative drug (such as nevirapine or raltegravir or a boosted PI) is often considered and would be a preferred option versus adding another drug (such as Letrozole) with added cost and risk for additional side effects. In a small number of reported cases such switching led to a reversal of the gynecomastia. KH
See below for background:
Gynecomastia in the Swiss HIV Cohort Study: An Association with Potent Antiretroviral Therapy
By Ronald Baker, PhD
Publisher and editor-in-chief, HIV and Hepatitis.com
Gynecomastia is defined as benign, excessive enlargement of the male mammary gland (breast). HIV-related gynecomastia develops mainly in men with preserved immunological status after years of HAART. Photographs of men affected by this syndrome are posted on the Internet at www.gynecomastia.org.
In a recently published Spanish study, researchers describe the clinical features and treatment of 34 HIV-positive men with gynecomastia in what they call "the largest series of gynecomastia reported in HIV-infected patients."
The patients came from a cohort of 1400 HIV-positive men. Of these, 900 were receiving antiretroviral therapy, the authors report, for an incidence of 2.4 cases per 100 patients receiving HAART per year.
In a recent observational longitudinal study, investigators report on five patients diagnosed with gynecomastia associated with efavirenz (Sustiva)-based HAART regimens. In all five cases, gynecomastia regressed after efavirenz withdrawal (mean period of 5 months).
In a letter to the editor of AIDS (June 18, 2004), researchers review the issue of HIV-related gynecomastia and report on its manifestation in the Swiss HIV Cohort study.
In HIV-1-uninfected individuals, gynecomastia is found most frequently during puberty, in elderly and obese individuals as well as in individuals with liver cirrhosis. The pathogenesis appears to be a hormonal imbalance such as a decreased ratio of androgens to estrogens or an increased tissue sensitivity to estrogens.
According to the authors, gynecomastia has also been associated with the use of spironolacton, digitalis compounds, cimetidine, enalapril, and amiodarone as well as heroin, marijuana, amphetamine, and alcohol consumption.
In HIV-1-infected individuals, the estimated prevalence ranges from 2 to 3%. Gynecomastia in HIV-1 infection may be associated with the use of potent antiretroviral therapy. Alternatively, gynecomastia has been interpreted as a distinct form of immune reconstitution illness. In addition, a significant relationship between the emergence of gynecomastia and the presence of the lipodystrophy syndrome has been noted.
Want to read more questions and answers on this subject? Our experts have answered many similar questions!
|